Researchers at the Norwegian university hospital AHUS have discovered and patented a new biomarker in blood enabling a convenient diagnostic tool for AD, even in the early disease stages. Pre Diagnostics has the rights to worldwide commercialization of the invention.
Prof. Tormod Fladby
Head of Department of Neurology, Akershus University Hospital (AHUS)
Professor II, Institute of Clinical Medicine, University of Oslo
Innate immune deficiency causes amyloid plaque formation in Alzheimer's disease and can be monitored in peripheral blood macrophages, where impeded Ab-degradation signals disease onset
Mid-domain amyloid beta peptides have been identified for diagnosis and monitoring of Alzheimer's disease
A prototype assay have been developed and applied successfully on clinical samples
A protein called beta-Amyloid accumulates in the diseased brain and destroys the nerve cells, a process that leads to dementia. Research has demonstrated that the breakdown of this protein is reduced in the cells responsible for removing beta-Amyloid, namely the macrophages of the brain. Researchers at AHUS, led by professor Tormod Fladby, have also discovered that blood macrophages show reduced degradation products of this protein. A prototype blood assay for this degradation product (beta-Amyloid 21-31) has verified that the assay performs similar to current tests of the whole protein in spinal fluid.
Patents protecting the invention have been filed in both Europe (EP2245463) and in the US (US 20110124010). The European Patent Office has informed Pre Diagnostics that it intends to grant a patent.